Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211527 | 0.98 | TDP1 (0.46) | TDP1SMN1; SMN2TSHRGFERHRH3 | |
| SCHEMBL10211529 | 0.87 | HRH3 (0.41) | SMN1; SMN2TSHRHRH3MEN1MAPT | |
| SCHEMBL13940622 | 0.87 | GFER (0.43) | TDP1SMN1; SMN2TSHRGFERKDM4E | |
| SCHEMBL10211525 | 0.85 | CYP2A13 (0.45) | HRH3MEN1KMT2A | |
| SCHEMBL2937177 | 0.84 | KDM4E (0.46) | TDP1SMN1; SMN2KDM4EMEN1MAPT | |
| SCHEMBL14132657 | 0.84 | ALDH1A1 (0.46) | TDP1HRH3MEN1MAPTKMT2A | |
| SCHEMBL14080538 | 0.79 | LDHA (0.41) | KDM4EMEN1KMT2A | |
| SCHEMBL14132351 | 0.77 | LMNA (0.40) | TDP1SMN1; SMN2HRH3KDM4EKMT2A | |
| SCHEMBL14049766 | 0.76 | HRH3 (0.41) | TDP1SMN1; SMN2HRH3KDM4EKMT2A | |
| SCHEMBL14080666 | 0.73 | HRH3 (0.36) | TDP1SMN1; SMN2TSHRGFERHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2712863-B1 | Novel inhibitors of bacterial biofilms and related methods | SEQUOIA SCIENCES INC (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2712863-B1 | Novel inhibitors of bacterial biofilms and related methods | SEQUOIA SCIENCES INC (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | SEQUOIA SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | SEQUOIA SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | SEQUOIA SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-8324264-B1 | Inhibitors of bacterial biofilms and related methods | SEQUOIA SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324264-B1 | Inhibitors of bacterial biofilms and related methods | SEQUOIA SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | BLVRB, MMP8, PGLS | TDP1 3533/4885SMN1; SMN2 4885/4885TSHR 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.